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Background: HLA-B27 is strongly associated with ankylosing spondylitis (AS).
Results: A change in the position (P) 2 anchor motif was detected in the 3% of HLA-B27 ligands identified, which showed
significant homology to pathogenic bacterial sequences.
Conclusion: Unusual HLA-B*2705 ligands bind with different conformations to both AS-associated and non-AS-associated
HLA-B27 subtypes.
Significance: This could be sufficient to initiate autoimmune damage in patients with AS-associated subtypes.
The presentation of short viral peptide antigens by human
leukocyte antigen (HLA) class I molecules on cell surfaces is a
key step in the activation of cytotoxic T lymphocytes, which
mediate the killing of pathogen-infected cells or initiate autoim-
mune tissue damage. HLA-B27 is a well known class I molecule
that is used to study both facets of the cellular immune response.
Using mass spectrometry analysis of complex HLA-bound pep-
tide pools isolated from large amounts of HLA-B*2705 cells,
we identified 200 naturally processedHLA-B*2705 ligands. Our
analyses revealed that a change in the position (P) 2 anchor
motif was detected in the 3% of HLA-B*2705 ligands identified.
B*2705 class I molecules were able to bind these six GlnP2 pep-
tides, which showed significant homology to pathogenic bacte-
rial sequences, with a broad range of affinities. One of these
ligands was able to bind with distinct conformations to HLA-
B27 subtypes differentially associated with ankylosing spondy-
litis. These conformational differences could be sufficient to
initiate autoimmune damage in patients with ankylosing spon-
dylitis-associated subtypes. Therefore, these kinds of peptides
(short, with GlnP2, and similar low affinity to all HLA-B27 sub-
types tested but with unlike conformations in differentially
ankylosing spondylitis-associated subtypes) must not be
excluded from future researches involving potential arthrito-
genic peptides.
Proteolytic degradation of self-proteins and pathogenic pro-
teins in the cytosol by the combined actions of the proteasomes
and degradative peptidases generates peptides, mostly of 8–10
residues, that are translocated to the endoplasmic reticulum
lumen by the transporter associated with antigen processing
(TAP)2 molecules. These short peptides assemble with human
leukocyte antigen (HLA) class I heavy chain and 2-micro-
globulin molecules (1). Typically, this interaction is made pos-
sible by two major anchor residues at position 2 (P2) and the C
terminus (C) of the antigenic peptide (2, 3) that are deeply
inserted into specific pockets of the antigen recognition site of
the HLA class I molecule (4, 5). Finally, the stable trimolecular
peptide-HLA-2-microglobulin complexes are transported to
the cell membrane and presented for cytotoxic T lymphocyte
recognition (6). This recognition of pathogenic or self-peptide
ligands can lead to the beneficial killing of pathogen-infected
cells or initiate a pathologic autoimmune damage respectively.
One of the most interesting class I HLA alleles is the HLA-
B27, which is strongly associated with ankylosing spondylitis
(AS), a chronic inflammatory spondyloarthropathy (7). Fur-
thermore, althoughmost of theHLA-B27 subtypes are strongly
associated with AS, HLA-B*2706 and -B*2709 are either not
associated or perhaps only weakly associated with this disease
(reviewed in Ref. 8), suggesting that this polymorphism subtype
modulates disease susceptibility. Previous studies show an
unambiguous functional distinction between the closely related
AS-associated B*2704 and non-AS-associated B*2706 subtypes
(9). However, after four decades of research, the basis for this
association remains an enigma. Several hypotheses, each based
on a particular feature of the HLA-B27 gene, have been pro-
posed to elucidate this intriguing association, but none have yet
satisfactorily explained the mechanism and the differential
association of HLA-B27 subtypes with disease. The arthrito-
genic peptide hypothesis (10) assumes that HLA-B27 can pres-
ent a microbial epitope, eliciting a normal cytotoxic T lympho-
cyte response against the pathogen. Unfortunately, some of
these cytotoxic T lymphocytes would cross-react with an autol-* This work was supported by grants from the Programa Ramón y Cajal and
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ogous self-ligand also presented by this molecule and show
molecular mimicry with the primary pathogenic epitope. This
cross-reaction promotes the autoimmune tissue injury and
inflammation. In this hypothesis, the differential binding or
immune recognition of either microbial or mimetic self-pep-
tide(s) between theHLAsubtypes explains the disparity in asso-
ciation with AS. The interest in this hypothesis has been highly
renewed by recent studies on the role of the interaction
between HLA-B27 and the endoplasmic reticulum aminopep-
tidase involved in the trimming of peptides for HLA class I
antigen presentation, ERAP1 (11, 12).
The major outstanding feature of HLA-B*2705 specificity is
its almost mandatory requirement for Arg at P2 (SYFPEITHI
database (3)). In contrast, two ligands with GlnP2 were identi-
fied (13, 14). To broaden this study, by means of an immuno-
proteomics analysis of peptide pools isolated from HLA-B27
cells the current study identifies, in addition to several hundred
HLA-B27 ArgP2 self-ligands, a small fraction of peptides con-
tainedGln at the P2 anchormotif. These peptides bind toHLA-
B27 subtypes with differential association with AS and show
significant homology to arthritogenic bacterial sequences.
EXPERIMENTAL PROCEDURES
Cell Lines and Antibodies—B27-C1R is an HLA-B*2705
transfectant (15) of the human lymphoid cell line HMy2.C1R
(C1R) that expresses endogenous HLA class I antigens at low
levels (16). RMA-S is a TAP-deficient murine cell line that
expresses themouseH-2b haplotype (17). TheRMA-S transfec-
tant cells expressing HLA-B*2705 (18), -B*2704 (19), or
-B*2706 (19) have been previously described. All cell lines were
cultured in RPMI 1640 supplemented with 10% fetal bovine
serum and 5 M -mercaptoethanol. Themonoclonal antibod-
ies (mAbs) used in this study wereW6/32 (specific for a mono-
morphicHLA-A, -B, and -C determinant) (20) andME1 (which
is specific for HLA-B27, -B7, and -Bw22) (21).
Synthesis of Peptides—Peptides were synthesized in a peptide
synthesizer (model 433A; Applied Biosystems, Foster City, CA)
and purified by reverse-phase HPLC. The molecular mass of
peptides was established with MALDI-TOFMS, and composi-
tion was determined by LC-MS/MS.
Isolation of HLA-bound Peptides—HLA-bound peptides
were isolated from 4  1010 B27-C1R transfectant cells as
described previously (22). Cells were lysed in 1% IGEPAL
CA-630 (Sigma), 20mMTris/HCl buffer, and 150mMNaCl, pH
7.5, in the presence of a protease inhibitor mixture. HLA-pep-
tide complexes were isolated by affinity chromatography of the
soluble fraction with the W6/32 mAb. HLA-bound peptides
were eluted at room temperature with 0.1% aqueous trifluoro-
acetic acid (TFA) and concentrated with a Centricon 3 column
(Amicon, Beverly, MA), as described previously (22).
Electrospray-Ion TrapMass Spectrometry Analysis—Peptide
mixtures recovered after the ultrafiltration step were concen-
trated with Micro-Tip reverse-phase columns (C18, 200 l,
Harvard Apparatus, Holliston, MA). Each C18 tip was equili-
brated with 80% acetonitrile in 0.1% TFA, washed with 0.1%
TFA, and then loaded with the peptide mixture. The tip was
then washed with an additional volume of 0.1% TFA, and the
peptideswere elutedwith 80%acetonitrile in 0.1%TFA. Peptide
samples were then concentrated to 18 l using vacuum
centrifugation.
RecoveredHLAclass I peptideswere analyzed in threeHPLC
procedures by LC-MS/MS using an Orbitrap XL mass spec-
trometer (Thermo Electron) fitted with a capillary HPLC col-
umn (Eksigent, Dublin, CA). The peptides were resolved on a
homemade ReproSil C18 capillary column (75-m inner diam-
eter) with a 7–40% acetonitrile gradient for 2 h in the presence
of 0.1% formic acid, as inRef. 22. The sevenmost intensemasses
that exhibited single-, double-, and triple-charge states were
selected for fragmentation by collision-induced dissociation
from each full mass spectrum.
Database Searches—Pep-Miner (23) was used for peak list
generation of the LC-MS/MS data. The HLA peptides were
identified using the following search engines: Pep-Miner (23);
Proteome Discoverer 1.0 SP1 (Thermo Electron), combining
the results of Sequest 3.31 and Bioworks Browser 3.3.1 SP1
(Thermo Electron) (24); and Mascot (server 2.2, Matrix Sci-
ence) (25), using the human and the viral sections of the
National Center for Biotechnology Information (NCBI) data-
base, which includes 448,769 proteins. The search was not lim-
ited by enzymatic specificity, the peptide tolerance was set to
0.005 Da, and the fragment ion tolerance was set to 0.5 Da.
Identified peptides were selected if the following criteria were
met: Pep-Miner score above 80;Mascot score above 20; Sequest
Xcorr 1.7 for singly charged, 2.2 for doubly charged, and
2.9 for triply charged peptides; Ppep less than 1  104 with
Bioworks Browser; Proteome Discovered score higher than 20;
and mass accuracy of 0.005 Da (22). When the MS/MS spectra
fitted more than one peptide, only the highest scoring peptide
was analyzed. The false positive rate for peptide identification
was set to 2% based on the search of a reversed database. In
addition, the corresponding synthetic peptides were made, and
their manually identified MS/MS spectra were used to confirm
the assigned sequence of HLA-B27 ligands.
MHC/Peptide Stability Assays—The following synthetic
peptides were used as controls in complex stability assays: Flu
NP (SRYWAIRTR, HLA-B27-restricted) (26) and C4CON
(QYDDAVYLK, HLA-Cw4-restricted) (27). RMA-S B*2705
transfectant cells, a cell line deficient in TAP that expresses low
levels of cell surface MHC class I, were incubated at 26 °C for
16 h in RPMI 1640medium supplemented with 10% heat-inac-
tivated FBS. This allows the expression of empty MHC class I
molecules (without antigenic peptide) at the cellularmembrane
that are stable at 26 °C but not at 37 °C. The cells were washed
and incubated for 2 h at 26 °C with various concentrations of
peptide in the same medium. The cells were maintained at
37 °C for an additional 4 h and then collected for flow cytom-
etry. This method allows empty MHC class I molecules to
become internalized and can thus discriminate between bound
and unbound peptides. MHC expression was measured using
100l of hybridoma culture supernatant containingME1 (anti-
HLA-B27) mAb as described previously (28). Data were
acquired on a FACSCalibur flow cytometer (BD Biosciences)
and analyzed using CellQuest Pro 2.0 software (BD Biosci-
ences). Cells incubated without peptides exhibited peak fluo-
rescence intensities close to the background staining observed
with secondary antibody alone. The fluorescence indexwas cal-
Natural HLA-B27 Peptidome with GlnP2
APRIL 12, 2013 • VOLUME 288 • NUMBER 15 JOURNAL OF BIOLOGICAL CHEMISTRY 10883










culated for each time point as the ratio of peak channel fluores-
cence of the sample to that of the control incubated without
peptide. Binding of peptides was also expressed as EC50, which
is the molar concentration of the peptide at 50% of the maxi-
mum fluorescence obtained in a concentration range of 100–
0.001 M.
Statistical Analysis—To analyze statistical significance, an
unpaired Student’s t test was used. p values  0.001 were con-
sidered to be significant.
RESULTS
HLA-B*2705 Peptidome—HLA-bound peptide pools were
isolated from large amounts of B27-C1R cells. This peptide
mixture was subsequently separated by reverse-phase HPLC
and analyzed by mass spectrometry. Using several software
technologies (see “Experimental Procedures”), 198 fragmenta-
tion spectra were resolved with high confidence parameters as
peptidic sequences of different human cellular proteins (data
not shown). As a control, a reverse database search of the same
HLA-B27-bound peptide pool showed a 2% false positive rate.
Arg or Gln as the HLA-B27 P2 Anchor Motif—The classical
anchor motif for HLA-B*2705 binding, Arg at the P2 residue
(SYFPEITHI database (3)), was present in 193 (97%) of the
detected ligands, and no differences with the HLA-B27 ligands
previously described were found (data not shown). In contrast,
this motif was absent in the other six ligands (Table 1).
Although virtually all significant fragments of all MS/MS spec-
tra were assigned as daughter ions of the tentative peptidic
sequence (supplemental Figs. 1–6, upper panels), the bioinfor-
matics assignment of each sequence was confirmed by identity
with the MS/MS spectrum of each corresponding synthetic
peptide (supplemental Figs. 1–6, lower panels). These confir-
mations of synthetic peptides indicate the correct database
assignment of the HLA-B27 peptidome.
Two of the ligands with GlnP2 had been previously detected
in an earlier study of theHLA-B*2705 peptidome (14) (Table 1).
One peptide was derived from the cartilage-related protein
ADAM10, two nested peptides were derived from the mono-
morphic2-microglobulin of theHLA class Imolecule, and the
last three were derived from a tumor antigen, a hypothetical
protein, and the SF3B2 protein, respectively (Table 1).
In summary, these results indicate that a total of six ligands
with absent ArgP2 anchormotifs were endogenously processed
and presented in the HLA-B*2705 cell line. In addition, these
data confirm that GlnP2 is an anchor motif derived from pep-
tides bound to the HLA-B*2705 class I molecule.
GlnP2 Ligands Bind to the B*2705 Molecule—Following a
similar strategy to the one used in this study, recent studies
have identified several hundred HLA-B27 ligands by immu-
noprecipitation with the W6/32 mAb of HLA-B27-peptide
complexes using the B27-C1R cell line (summarized in the
SYFPEITHI database (3)). As these six ligands with GlnP2 do
not possess the major HLA-B27 anchor motif ArgP2, one
possibility is that they could have a defective interaction with
the HLA-B27 class I molecule. To test this hypothesis, MHC/
peptide complex stability assays were carried out using TAP-
deficient RMA-S cells transfected with HLA-B*2705 and three
of the six noncanonical ligands. These included the larger
(IQRTPKIQVY) and shorter (RQPQVSI) ligands as well as a
nonamer (GQYGNPLNK). The GQYGNPLNK synthetic pep-
tide induced similar numbers of HLA-peptide surface com-
plexes to a well knownHLA-B*2705 epitope from the influenza
virus, whereas the other two peptides induced fewer HLA-
B*2705-peptide complexes (Fig. 1A). In addition, the relative
MHC class I affinity was determined for all peptides. The
GQYGNPLNKpeptide bound toHLA-B*2705 class Imolecules
with EC50 values in the range commonly observed among nat-
ural ligands (Fig. 1B). In contrast, theHLA affinity was substan-
tially less for the IQRTPKIQVY (EC50, 57  14) and RQPQVSI
(EC50, 200  21) peptides, and thus, these peptides must be
considered as medium and low affinity ligands, respectively
(Fig. 1B). These data indicate that all ligands detected in the
B27-C1R cell line were endogenously presented in association
with the B*2705 molecule and that this molecule could bind
peptides with a broad range of affinities.
Binding of the RQPQVSI Peptide to HLA-B*2705 Molecules—
Peptides without an N-terminal interaction with the HLAmol-
ecule have been identified as endogenously bound to HLA-B39
(29) and themurineMHC class I molecule H-2Dd (30), indicat-
ing that canonical MHC-peptide interactions in the P1 pocket
are not always necessary for endogenous peptide presentation.
Usually, the HLA-B*2705molecule binds peptides of 8–13 res-
idues (3, 31), but in this study, a 7-mer was found bound to this
HLA class I molecule. One possibility for this is that the short
RQPQVSI peptide binds to HLA-B27 molecules in the same
manner that other peptides lacking theN-terminal binding res-
idue do. Thus, new HLA-B*2705/peptide complex stability
assays were carried out exchanging either the ArgP1 or the
GlnP2 residues of the RQPQVSI peptide for alanine. Fig. 2
shows similar binding affinities for both the HLA-B*2705 nat-
ural ligands and the single Ala-substituted peptides. The
exchange of both ArgP1 and GlnP2 residues by Ala abrogated
binding to HLA-B*2705 molecules. Collectively, these data
indicate that ArgP1 as well as GlnP2 residues of the RQPQVSI
TABLE 1
Summary of endogenous ligands with Gln2 detected by MS/MS analysis
CTCL, cutaneous T-cell lymphoma.
Sequencea Protein Position gi
GQYGNPLNKb ADAM10 18–26 116496847
IQRTPKIQ 2-Microglobulin 21–28 114319011
IQRTPKIQVY 2-Microglobulin 21–30 114319011
DQLQEQLQR CTCL antigen HD-CL-01/ L14–2 545–553 36031016
RQPQVSI Hypothetical protein 185–191 113430821
RQTGIVLNRb SF3B2 59–67 119594903
a The new HLA-B27 anchor motif is underlined.
b Previously reported (13, 14).
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peptide are sufficient to support interactions with class I
molecules.
GlnP2 Ligands Bind to HLA-B27 Subtypes with Differential
Association with Ankylosing Spondylitis—In contrast to HLA-
B*2705, some HLA-B27 subtypes are not associated with AS
(reviewed in Ref. 8). Thus, we selected a pair of HLA-B27 sub-
types with differential association with this autoimmune dis-
ease. Although HLA-B*2706 is not associated with AS, its most
relatedHLA-B27 subtype, B*2704, is an AS-associated subtype.
Thus, a comparison of the specific binding of these HLA class I
molecules to peptides with noncanonical GlnP2 residues was
carried out. The binding to HLA-B*2706 was significantly
less than that of B*2704 (and the B*2705) with both the
GQYGNPLNK and the IQRTPKIQVY peptides; thus, these pep-
tidesmust be considered low affinity ligands in the subtype asso-
ciated with AS (Fig. 3). No differences in binding were found
with the RQPQVSI peptide in both subtypes (Fig. 3). In sum-
mary, the three GlnP2 peptides studied bound to HLA-B*2706
with relatively low affinity. In addition, the differential binding
between the B*2704 and B*2706 subtypes detected with the
GQYGNPLNK and IQRTPKIQVY peptides, but not with
RQPQVSI peptide, correlatedwith the previously reported rep-
ertoire of ArgP2 peptide specificity of these subtypes, where
B*2704 but not B*2706 favors the binding of Tyr or Arg at res-
idue carboxy-terminal of a peptide (P) (32).
Differential Binding of the RQPQVSI Peptide to HLA-B27
Subtypes with Disparate Association with Ankylosing
Spondylitis—The RQPQVSI peptide bound to the HLA-
B*2704 and -B*2706 subtypes with similarly low affinities (Fig.
3). To study the requirements of the binding of these peptides
to the related HLA-B27 subtypes, the exchange of alanine for
either theArgP1or theGlnP2 residues of theRQPQVSI peptide
was tested in complex stability assays. The relative binding to
the B*2704 subtype of both natural ligands and Ala-substituted
peptides was identical (Fig. 4, left panel). Thus, the RQPQVSI
peptide bound in similar ways to two different AS-associated
subtypes, B*2705 and B*2704. On the other hand, the ArgP1
residue of the RQPQVSI peptide is critical for binding to the
B*2706 subtype (Fig. 4, right panel) but not to the B*2704 sub-
FIGURE 1. HLA-B*2705 stabilization assay of synthetic ligands. A, stability of HLA-B*2705/peptide complexes on the surface of RMA-S transfectant cells was
measured by flow cytometry. The indicated peptides were used at 200 M. Significant p values: ***, p  0.001. B, the titration curves of synthetic GQYGNPLNK
(circles), IQRTPKIQVY (triangles), and RQPQVSI (diamonds) peptides with HLA-B*2705 are depicted. The C4CON (solid line) (27) and Flu NP (squares) (26) peptides
were used as negative and positive controls, respectively. The results, calculated as the fluorescence index (panel A) or EC50 values  S.D. (panel B), are the mean
of three or four independent experiments.
FIGURE 2. HLA-B*2705 stabilization assay of synthetic peptide RQPQVSI
with Ala substitutions in anchor motifs. The stability of HLA-B*2705/pep-
tide complexes on the surface of RMA-S transfectant cells was measured by
flow cytometry. The titration curves of synthetic RQPQVSI (circles), AQPQVSI
(diamonds), RAPQVSI (triangles), and AAPQVSI (squares) peptides with HLA-
B*2705 are depicted. The results, which are the means of three independent
experiments, are as shown in Fig. 1B.
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type (Fig. 4, left panel). Thus, in the interactions of this subtype
with the RQPQVSI peptide, the ArgP1 residue is the anchor
motif andmediates binding to this subtype, as do other peptides
lacking the N-terminal binding residue (29, 30). In summary,
the RQPQVSI peptide bound with a comparably low affinity,
but with different conformation, to HLA-B27 subtypes associ-
ated (B*2705 andB*2704) or not associated (B*2706) with anky-
losing spondylitis (Table 2).
Homology of GlnP2 Ligands with Pathogenic Bacterial
Sequences—A comparison of the sequences of six natural
HLA-B27 GlnP2 ligands identified in the current study with
12 species of bacteria associated with HLA-B27-dependent
reactive arthritis (33) was carried out. Table 3 shows diverse
bacterial sequences that differ from endogenous HLA-B27
peptides by 2–3 residues. Most of these changes are in sur-
face-exposed regions of proteins; thus, they could modulate
differential interactions with the T-cell receptor as com-
pared with endogenous cellular HLA-B27 peptides as shown
in the HLA-B*2705 crystal structure (34) (PDB: 1HSA). In
addition, four proteins with HLA-B27 GlnP2 ligands,
ADAM10, 2-microglobulin, cutaneous T-cell lymphoma
antigen, and SF3B2, were included in a network of connec-
tive tissue disorders and inflammatory disease following
analysis with the Ingenuity Pathway Analysis software.
DISCUSSION
In this study, we have investigated several issues concern-
ing the processing of natural HLA-B*2705 ligands, including
the analysis of a refined binding motif and the binding of
GlnP2 ligands to HLA-B27 subtypes differentially associated
with AS. Previously, some HLA-B*2705 ligands with GlnP2
had been described (13, 14). In the present study, this change
in the P2 anchor motif was detected in the 3% of HLA-
B*2705 ligands identified. Thus, these data confirm the
refined HLA-B*2705 binding motif. In addition, five of six
ligands identified by mass spectrometry analysis show the
preferential residue usage both P1 and/or P positions pre-
viously described from canonical HLA-B*2705 ligands (14,
35). Thus, the GlnP2 ligands could interact with the pockets
of the HLA class I-presenting molecule in the same way
those ArgP2 canonical ligands.
Five of the six ligands with GlnP2 were derived from four
proteins included in a network of connective tissue disorders.
ADAM10 is a chondrocyte-derivedmetalloproteinase involved
in joint pathology (36, 37). The 2-microglobulin is associated
withHLAclass I heavy chains and reducesHLA-B27misfolding
promoting arthritis and spondylitis in HLA-B27-transgenic
rats (38). HD-CL-01 is an antigen of cutaneous T-cell lym-
phoma, and polyarthritis in the presence of this lymphoma is a
phenomenon previously described (39–41). Lastly, SF3B2 is a
component of the spliceosome complex (42) that has been
linked to rheumatoid arthritis and several connective tissue dis-
eases (43, 44).
All these human HLA-B27 GlnP2 ligands have homology
with distinct arthritogenic bacterial sequences that differ from
these endogenousHLA-B27 peptides by 2–3 residues. Remark-
ably, several arthritogenic bacterial sequences possess changes
in the ArgP1 of the RQPQVSI sequence that could alter the
binding conformations between the different subtypes of HLA-
B27 associated or not associated with AS.
The observation that HLA-B*2704 and -B*2706 subtypes
share a very broad fraction of90% of their peptide repertoires
(32) suggests that putative arthritogenic peptides could be con-
fined in a first approximation to a relatively small portion of
ligands shared by AS-associated subtypes such as B*2705 and
B*2704 that are missing from the B*2706 peptide repertoire.
FIGURE 3. HLA stabilization assay of subtypes with differential associa-
tion with ankylosing spondylitis of synthetic ligands. The stability of HLA-
B*2704 (left panel) or HLA-B*2706 (right panel)/peptide complexes on the sur-
face of RMA-S transfectant cells was measured by flow cytometry. The code
used and the results, which represent the means of three independent exper-
iments, are as shown in Fig. 1B. Also, the calculated EC50 values  S.D. are
shown in the lower panel.
FIGURE 4. HLA stabilization assay of subtypes with differential associa-
tion with ankylosing spondylitis of synthetic peptide RQPQVSI with Ala
substitutions in anchor motifs. The stability of HLA-B*27/peptide complexes
on the surface of RMA-S transfectant cells was measured by flow cytometry. The
titration curves of synthetic RQPQVSI (circles), AQPQVSI (diamonds), RAPQVSI (tri-
angles), and AAPQVSI (squares) peptides with HLA-B*2704 (left panel) or -B*2706
(right panel) are depicted. The results, which represent the means of three inde-
pendent experiments, are as shown in Fig. 1B.
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The self-derived ligands with GlnP2, analyzed in the current
study, bind to AS-associated class I subtypes (HLA-B*2705 and
-B*2704) with a broad range of affinities, whereas they have
shown a low affinity in their interaction with the non-AS-asso-
ciated HLA-B*2706 allele. Thus, the differences of affinity in
self-derived ligands could trigger autoimmune tissue injury in
AS-associated versus non-AS-associated HLA-B27 class I pos-
itive individuals. In addition, our study indicates that some
unusual HLA-B*2705 ligands, such as the RQPQVSI peptide,
bind with similar affinity but different conformations to both
AS-associated and non-AS-associated HLA-B27 subtypes. The
HLA-B27 subtype-dependent conformation of canonical
ArgP2 self-peptides was previously described (45, 46). Thus,
these conformational differences, which could be detected by
the fine specificity of autoreactive cytotoxic T lymphocytes,
could be sufficient to initiate autoimmune damage in patients
withAS-associated subtypes. Therefore, these kinds of peptides
(short, with GlnP2, and with similar low affinity to all HLA-B27
subtypes tested but with dissimilar conformations in differen-
tially AS-associated subtypes) must not be excluded from
future research involving potential arthritogenic peptides.
In summary, these results inform us about the interaction
between unusual GlnP2 self-derived ligands and different
HLA-B27 subtypes in the pathogenic role of these class I mol-
ecules in the triggering of AS autoimmune disease.
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8. Marcilla,M., and López deCastro, J. A. (2008) Peptides: the cornerstone of
HLA-B27 biology and pathogenetic role in spondyloarthritis. Tissue An-
tigens 71, 495–506
9. López, D., Rojo, S., Calvo, V., and López de Castro, J. A. (1992) Peptide-
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topology of an HLA-B27 allospecific T cell epitope lacking peptide speci-
ficity. J. Immunol. 152, 2317–2323
19. Galocha, B., Lamas, J. R., Villadangos, J. A., Albar, J. P., and López de
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30. Samino, Y., López, D., Guil, S., de León, P., and Del Val, M. (2004) An
endogenous HIV envelope-derived peptide without the terminal NH3
group anchor is physiologically presented by major histocompatibility
complex class I molecules. J. Biol. Chem. 279, 1151–1160
31. Sesma, L., Galocha, B., Vázquez,M., Purcell, A.W.,Marcilla, M., McClus-
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Supplemental Figure 1. Identification of the GQYGNPLNK ligand in cell extracts 
by mass spectrometry 
MS/MS fragmentation spectra obtained from quadrupole ion trap mass spectrometry of 
the ion peak at m/z 990.5 from the B27-C1R cell extract (upper panel) and the 
corresponding synthetic peptide (lower panel). The vertical axis represents the relative 
abundance of the parental ion and each fragmentation ion detected. Ions generated in 
the fragmentation are detailed, and the sequence deduced from the indicated 
fragments is shown in the upper left box of each panel. 
 
Supplemental Figure 2. Identification of the IQRTPKIQ ligand in cell extracts by 
mass spectrometry 
MS/MS fragmentation spectra obtained from quadrupole ion trap mass spectrometry of 
the ion peak at m/z 492.3 from the B27-C1R cell extract (upper panel) and the 
corresponding synthetic peptide (lower panel). The axis data are as shown in 
Supplemental Figure 1. 
 
Supplemental Figure 3. Identification of the IQRTPKIQVY ligand in cell extracts 
by mass spectrometry 
MS/MS fragmentation spectra obtained from quadrupole ion trap mass spectrometry of 
the ion peak at m/z 623.4 from the B27-C1R cell extract (upper panel) and the 
corresponding synthetic peptide (lower panel). The axis data are as shown in 
Supplemental Figure 1. 
 
Supplemental Figure 4. Identification of the DQLQEQLQR ligand in cell extracts 
by mass spectrometry 
 2 
MS/MS fragmentation spectra obtained from quadrupole ion trap mass spectrometry of 
the ion peak at m/z 579.3 from the B27-C1R cell extract (upper panel) and the 
corresponding synthetic peptide (lower panel). The axis data are as shown in 
Supplemental Figure 1. 
 
Supplemental Figure 5. Identification of the RQPQVSI ligand in cell extracts by 
mass spectrometry 
MS/MS fragmentation spectra obtained from quadrupole ion trap mass spectrometry of 
the ion peak at m/z 414.2 from the B27-C1R cell extract (upper panel) and the 
corresponding synthetic peptide (lower panel). The axis data are as shown in 
Supplemental Figure 1. 
 
Supplemental Figure 6. Identification of the RQTGIVLNR ligand in cell extracts by 
mass spectrometry 
MS/MS fragmentation spectra obtained from quadrupole ion trap mass spectrometry of 
the ion peak at m/z 528.8 from the B27-C1R cell extract (upper panel) and the 
corresponding synthetic peptide (lower panel). The axis data are as shown 
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